温阳消癥方治疗阳虚血瘀型慢性肾脏病3 期临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R692;R277.5

基金项目:

宁波市医学科技计划项目(2021Y21);宁波市医学重点学科建设项目(2022-Z02)


Clinical Study on Wenyang Xiaozheng Prescription for Stage 3 Chronic Kidney Disease of Yang Deficiency and Blood Stasis Type
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察温阳消癥方治疗阳虚血瘀型慢性肾脏病3期患者的临床疗效。方法:将104名阳虚血瘀 型慢性肾脏病3期患者按随机数字表法分为对照组和试验组各52例。对照组给予一般基础治疗,试验组在对照 组基础上口服温阳消癥方。2组均治疗8周。比较2组治疗前后中医证候积分、肾功能、24 h尿蛋白、血白蛋 白、尿转化生长因子-β1 (TGF-β1),并比较2 组临床疗效及不良反应发生情况。结果:试验组总有效率 67.31%,高于对照组32.69% (P<0.05)。治疗后,2组中医证候积分均降低(P<0.05),且试验组低于对照 组(P<0.05)。治疗后,2组尿素氮、血肌酐均降低(P<0.05),且试验组低于对照组(P<0.05),2组肾小球 滤过率(GFR) 升高(P<0.05),且试验组高于对照组(P<0.05)。治疗后,试验组血清白蛋白升高(P< 0.05),且高于对照组(P<0.05);2组尿TGF-β1降低(P<0.05),且试验组低于对照组(P<0.05);2组24 h 尿蛋白与治疗前比较,差异无统计学意义(P>0.05)。2组均未见明显不良反应发生。结论:温阳消癥方治疗 阳虚血瘀型慢性肾脏病3期临床疗效确切,可改善患者的临床症状,提高血清白蛋白,降低尿TGF-β1,改善 肾功能,且安全性高。

    Abstract:

    Abstract : Objective : To observe the clinical effect of Wenyang Xiaozheng Prescription on stage 3 chronic kidney disease of yang deficiency and blood stasis type. Methods: A total of 104 patients with stage 3 chronic kidney disease of yang deficiency and blood stasis type were randomly divided into the control group and the trial group according to the random number table method, with 52 cases in each group. The control group received general basic treatment,and the trial group received oral administration of Wenyang Xiaozheng Prescription based on the treatment of the control group. Both groups were treated for eight weeks. The traditional Chinese medicine syndrome scores,kidney function,24-hour proteinuria, blood albumin,and urinary transforming growth factor-β1 (TGF-β1) before and after treatment,as well as the clinical effects and incidence of adverse reactions were compared between the two groups. Results: The total effective rate was 67.31% in the trial group,higher than that of 32.69% in the control group (P< 0.05). After treatment, the traditional Chinese medicine syndrome scores in the two groups were decreased (P<0.05), and the score in the trial group was lower than that in the control group (P<0.05). After treatment,urea nitrogen and blood creatinine in the two groups were decreased (P<0.05),and the indexes in the trial group were lower than those in the control group (P<0.05). Glomerular filtration rate (GFR) in the two groups were increased (P<0.05),and the one in the trial group was higher than that in the control group (P<0.05). After treatment, the blood albumin levels in the trial group were increased (P< 0.05), and the level in the trial group was higher than that in the control group (P<0.05). The levels of urinary TGF-β1 in the two groups were decreased (P<0.05),and the level in the trial group was lower than that in the control group (P<0.05);There was no significant difference of 24-hour proteinuria between the two groups before and after treatment (P>0.05). No significant adverse reactions were observed in the two groups. Conclusion:Wenyang Xiaozheng Prescription has a definite clinical effect in treating stage 3 chronic kidney disease of yang deficiency and blood stasis type, which can improve the clinical symptoms, increase serum albumin,and reduce urinary TGF-β1,improve kidney function with high safety.

    参考文献
    相似文献
    引证文献
引用本文

周露,邢洁,蔡旭东,贾占东,谢文佳.温阳消癥方治疗阳虚血瘀型慢性肾脏病3 期临床研究[J].新中医,2024,56(13):112-116

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-07-10
  • 出版日期:
文章二维码